Clinical guideline
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
J Natl Compr Canc Netw · 2026
Studies and guidelines: Breast cancer
98 items with a structured summary · Breast cancer: the complete guide
Clinical guideline
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2024
Clinical guideline
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer
ESMO Open · 2024
Clinical guideline
Screening for Breast Cancer
JAMA · 2024
Moderate net benefitBiennial screening mammography, ages 40 to 74 years
Clinical guideline
Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR
Journal of the American College of Radiology · 2023
Annual screening from age 40Screening of women at average risk
Clinical guideline
Breast Cancer Screening for Women at Average Risk
JAMA · 2015
Reduction in breast cancer mortality across a range of study designsScreening mammography at ages 40 to 69
Clinical guideline
Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update
JCO · 2013
14 studiesNew studies included
Review article
Antibody–drug conjugates in breast cancer: the first-line and curative setting
Current Opinion in Oncology · 2026
Its role in first-line metastatic and perioperative treatment was established (DESTINY-Breast09, DESTINY-Breast05 and DESTINY-Breast11)Trastuzumab deruxtecan (T-DXd) in HER2-positive breast cancer
Clinical trial · Phase 3
Overall survival with abemaciclib in early breast cancer
Ann Oncol · 2026
0.842 (95% CI 0.722–0.981)Overall survival (HR)
Clinical trial · Phase 3
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
N Engl J Med · 2026
44.3 months vs 29.1 months (palbociclib vs standard therapy)Median progression-free survival
Clinical trial · Phase 3
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial
Ann Oncol · 2026
0.65 (95% CI: 0.53 to 0.78)Invasive disease-free survival (HR)
Clinical trial · Phase 3
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
N Engl J Med · 2026
92.4% vs 83.7%3-year invasive disease-free survival
Clinical trial · Phase 3
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
N Engl J Med · 2026
40.7 vs 26.9 monthsMedian progression-free survival
Clinical trial · Phase 3
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
N Engl J Med · 2025
8.4 yearsMedian follow-up
Review article
Breast cancer statistics 2024
CA A Cancer J Clinicians · 2024
Increase of 1% per yearTrend in breast cancer incidence (2012 to 2021)
Clinical trial · Phase 3
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
N Engl J Med · 2024
86.6% vs 81.7% (pembrolizumab–chemotherapy vs placebo–chemotherapy)Estimated overall survival at 60 months
Clinical trial · Phase 3
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
N Engl J Med · 2024
13.2 vs 8.1 monthsProgression-free survival (HER2-low)
Clinical trial · Phase 3b/4
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Nat Med · 2024
61.6%12-month progression-free survival (brain metastasis cohort)
Clinical trial · Phase 3
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Nat Med · 2024
52.6 vs 42.7 monthsMedian overall survival
Clinical trial
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
N Engl J Med · 2023
368 women (74.0%)Women with at least one pregnancy (of 497 women followed for pregnancy status)
Clinical trial · Phase 3
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
N Engl J Med · 2022
23.0 months vs 16.1 monthsMedian overall survival (CPS ≥10)
Clinical trial · Phase 3
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
N Engl J Med · 2022
10.1 vs 5.4 monthsProgression-free survival (hormone receptor-positive)
Review article
Breast cancer
The Lancet · 2021
Other
Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors
JAMA Dermatol · 2021
Diffuse non-scarring alopecia (n = 39), female pattern hair loss (n = 55), male pattern hair loss (n = 6)Pattern of hair loss
Clinical trial · Phase 3
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
JCO · 2020
HR 0.75 (95% CI 0.60–0.93)Invasive disease-free survival (IDFS)
Observational study
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)
JCO · 2020
Adjusted HR 1.41 (95% CI 0.98 to 2.04)Any antioxidant supplement (vitamins A, C and E; carotenoids; coenzyme Q10) before and during treatment — recurrence
Clinical trial · Phase 3
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
The Lancet · 2020
31 patients (40 Gy), 27 patients (27 Gy), 21 patients (26 Gy)Ipsilateral breast tumour relapse (number of events)
Clinical trial
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial
JAMA · 2019
69.3% vs 72.7%Ambulatory (grade 1 or 2) at week 8 — primary outcome
Observational study
Sugary drink consumption and risk of cancer: results from NutriNet-Santé prospective cohort
BMJ · 2019
Sub-distribution hazard ratio 1.18 (95% CI: 1.10 to 1.27); 2193 casesOverall cancer and sugary drink intake (per 100 mL/day increase)
Clinical trial · Phase 3
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
N Engl J Med · 2018
HR 1.08iDFS (endocrine therapy vs chemo + endocrine)
Meta-analysis
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient–Level Data
JCO · 2018
14.1% in the GnRHa group vs 30.9% in the control groupPremature ovarian insufficiency (POI) rate
Clinical trial
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N Engl J Med · 2018
34.9 months (95% CI: 28.8 to 40.0) vs 28.0 months (95% CI: 23.6 to 34.6)Median overall survival in all patients
Observational study
Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
The Oncologist · 2018
39.5%Proportion of patients with PCIA at 6 months
Meta-analysis
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
N Engl J Med · 2017
13%Risk of distant recurrence, T1N0
Clinical trial
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N Engl J Med · 2017
74.1% vs 67.6%Disease-free survival at 5 years (all patients)
Clinical trial
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
N Engl J Med · 2017
171 patients (7.1%) vs 210 patients (8.7%)Disease recurrence
Observational study
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer
JAMA · 2017
66.3% (67 of 101 patients) in the scalp cooling group vs 0% (0 of 16 patients) in the control groupHair loss of 50% or less (Dean score 0 to 2) in evaluable patients
Clinical trial
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer
JAMA · 2017
48 of 95 (50.5%)Successful hair preservation (after 4 chemotherapy cycles) in the cooling group
Clinical trial
Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial
JNCI: Journal of the National Cancer Institute · 2017
27.8% vs 80.6%Tactile sensitivity - hand (intervention vs control)
Clinical trial
Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial
Support Care Cancer · 2017
0.46-unit reduction in the exercise group versus controlHot/cold symptoms in the hands/feet
Clinical trial · Phase 2
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Clinical Cancer Research · 2017
19.7%Confirmed objective response rate (primary objective)
Clinical trial · Phase 3
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
JCO · 2017
16.4 vs 9.3 monthsMedian PFS
Clinical trial · Phase 3
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
JCO · 2017
HR 0.54 (95% CI 0.41–0.72)Progression-free survival (PFS)
Clinical trial · Phase 3
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
N Engl J Med · 2017
7.0 months vs 4.2 months (olaparib vs standard therapy)Median PFS (median progression-free survival)
Clinical trial · Phase 2
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial
The Lancet Oncology · 2017
2% (2 of 85 patients) vs 33% (159 of 482 patients) in BOLERO-2Incidence of grade 2 or worse stomatitis by week 8
Observational study
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
JAMA · 2017
72% in BRCA1 carriers and 69% in BRCA2 carriersCumulative breast cancer risk to age 80
Meta-analysis
Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis
Breast Cancer Res Treat · 2017
24 full-text papers; 10 papers with quantitative reporting of scalp metastasis incidencePapers reviewed
Clinical trial · Phase 3
Palbociclib and Letrozole in Advanced Breast Cancer
N Engl J Med · 2016
24.8 months vs 14.5 monthsMedian PFS (median progression-free survival)
Meta-analysis
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
The Lancet · 2015
RR 0.94 (95% CI 0.87–1.01)Recurrence (all patients)
Meta-analysis
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
The Lancet · 2015
RR 0.64Comparison 1: recurrence in years 0 to 1 (5 years of an aromatase inhibitor vs 5 years of tamoxifen)
Clinical trial · Phase 3
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
Annals of Oncology · 2015
1.17 ± 1.11 (biosimilar, 101 patients) vs 1.20 ± 1.02 (reference, 103 patients)Duration of severe neutropenia in the first cycle (days)
Observational study
Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy
Clinical Breast Cancer · 2015
10% of patientsNeed for a wig/head covering at the follow-up visit
Clinical trial
Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy
N Engl J Med · 2015
8% vs 22% (goserelin vs chemotherapy alone)Ovarian failure at 2 years (135 patients with complete data)
Clinical trial · Phase 3
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
N Engl J Med · 2015
56.5 months vs 40.8 monthsMedian overall survival
Clinical trial
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
The Lancet · 2013
617 recurrences among 3428 women vs 711 recurrences among 3418 womenBreast cancer recurrence (ER positive)
Meta-analysis
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
The Lancet · 2012
RR 0.86 (SE 0.04)Adding four cycles of a taxane to a fixed anthracycline-based control regimen (extended treatment) – breast cancer mortality
Clinical trial · Phase 2
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
The Lancet Oncology · 2012
45.8% (49 of 107 patients; 95% CI: 36.1 to 55.7)Pathological complete response in group B (pertuzumab + trastuzumab + docetaxel)
Clinical trial · Phase 3
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
N Engl J Med · 2012
6.9 months vs 2.8 monthsMedian progression-free survival (local investigator assessment)
Clinical trial · Phase 3
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
N Engl J Med · 2012
9.6 months vs 6.4 monthsMedian progression-free survival (independent review)
Clinical trial · Phase 3
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
N Engl J Med · 2011
75% (AC-T) vs 84% (AC-T plus trastuzumab) vs 81% (TCH)5-year disease-free survival
Meta-analysis
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
The Lancet · 2011
RR 0.53 (SE 0.03)Recurrence rate ratio in ER-positive disease, years 0 to 4
Clinical trial · Phase 3
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
N Engl J Med · 2005
351 events in the letrozole group vs 428 events in the tamoxifen groupNumber of events
Clinical trial
Adjuvant Docetaxel for Node-Positive Breast Cancer
N Engl J Med · 2005
75% vs 68% (TAC vs FAC)5-year disease-free survival (median follow-up 55 months)
Clinical trial
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
N Engl J Med · 2005
127 events with trastuzumab vs 220 events in the observation group (347 in total)Number of events at the first interim analysis (median follow-up one year)
Clinical trial
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
N Engl J Med · 2005
133 events in the trastuzumab group vs 261 events in the control group (total 394)Number of events (recurrence, second primary cancer or death before recurrence) up to 15 March 2005
Clinical trial
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
N Engl J Med · 2003
75 in the letrozole group vs 132 in the placebo group (207 in total)Number of events (local or metastatic recurrence or new primary cancer in the contralateral breast)
Clinical trial
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
JCO · 2003
69% / 66% / 67%5-year disease-free survival by doxorubicin dose (60 / 75 / 90 mg/m²)
Clinical trial
Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer
N Engl J Med · 2002
30 patients in the breast-conserving surgery group vs 8 patients in the radical mastectomy groupTumour recurrence in the same breast (number of patients)
Clinical trial · Phase 3
Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group
JCO · 2001
41 vs 26 weeks (letrozole vs tamoxifen)Time to progression (TTP), median
Clinical trial
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
N Engl J Med · 2001
7.4 vs 4.6 monthsTime to disease progression (median)
Clinical trial · Phase 3
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
JNCI: Journal of the National Cancer Institute · 1998
49%Reduction in risk of invasive breast cancer
Clinical trial
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
JCO · 2020
HR 0.32 (95% CI 0.22–0.48); 68% risk reductionCNS-PFS (risk of intracranial progression or death)
Clinical trial
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
The Lancet · 2014
40 women (2%) in the anastrozole group vs 85 women (4%) in the placebo groupBreast cancer (median follow-up 5.0 years; interquartile range 3.0–7.1)
Clinical trial
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
The Lancet Oncology · 2010
HR 0.91 (95% CI 0.83 to 0.99)Disease-free survival (whole population)
Clinical trial
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
The Lancet · 2002
89.4% vs 87.4%3-year disease-free survival: anastrozole versus tamoxifen
Review article
Dynamic circulating tumor DNA profiling of ESR1 mutations in HR+/HER2− advanced breast cancer: from prognostic biomarker to clinical decision-making – a comprehensive review
Front. Oncol. · 2026
HR 0.58PFS2 in patients with high ctDNA tumour fraction (≥10%) on first-line CDK4/6i
Clinical trial · Phase 3
Giredestrant plus Everolimus in Advanced Breast Cancer
N Engl J Med · 2026
10.0 vs 5.5 monthsMedian progression-free survival – ESR1-mutated
Meta-analysis
Oral selective estrogen receptor degraders in ER+/HER2− breast cancer: a systematic review with pooled analysis of metastatic randomized trials and narrative synthesis of adjuvant evidence
Front. Oncol. · 2026
HR 0.70 (95% CI: 0.57 to 0.87)Invasive disease-free survival (iDFS) with adjuvant giredestrant (lidERA)
Clinical trial · Phase 3
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
N Engl J Med · 2026
11.2 vs 7.8 monthsMedian progression-free survival
Clinical trial · Phase 3
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
ESMO Open · 2025
0.716 (95% CI 0.618–0.829)Invasive disease-free survival (HR)
Clinical trial · Phase 3
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
N Engl J Med · 2025
16.0 vs 9.2 monthsMedian progression-free survival
Clinical trial · Phase 3
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
N Engl J Med · 2025
5.5 months vs 3.8 monthsMedian PFS — patients with ESR1 mutations (imlunestrant vs standard therapy)
Clinical trial · Phase 3
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
N Engl J Med · 2024
15.0 months vs 7.3 months (inavolisib group vs placebo group)Median progression-free survival
Clinical trial · Phase 3
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
N Engl J Med · 2022
6.6 yearsMedian follow-up
Clinical trial · Phase 3
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
N Engl J Med · 2021
5.6 vs 1.7 monthsMedian progression-free survival
Clinical trial · Phase 3
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
N Engl J Med · 2020
167 of 484 patients (34.5%) vs 108 of 242 patients (44.6%)Number of deaths
Clinical trial · Phase 3
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
N Engl J Med · 2019
83 of 335 patients (24.8%) vs 109 of 337 patients (32.3%)Deaths
Clinical trial · Phase 3
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
JCO · 2018
20.5 months vs 12.8 monthsMedian PFS
Clinical trial · Phase 3
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
J Clin Oncol · 2024
HR 0.680IDFS (median follow-up 54 months)
Clinical trial · Phase 3
Ribociclib plus Endocrine Therapy in Early Breast Cancer
N Engl J Med · 2024
90.4% vs 87.1%3-year iDFS
Clinical trial · Phase 3
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
N Engl J Med · 2022
75.8% vs 34.1%Alive and progression-free at 12 months
Clinical trial · Phase 3
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
N Engl J Med · 2021
85.9% vs 77.1%Three-year iDFS
Clinical trial · Phase 3
Pembrolizumab for Early Triple-Negative Breast Cancer
N Engl J Med · 2020
64.8% vs 51.2%Pathological complete response
Clinical trial · Phase 3
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
N Engl J Med · 2019
88.3% vs 77.0%3-year iDFS
Clinical trial · Phase 3
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
The Lancet Oncology · 2018
23.8 months vs 13.0 monthsMedian progression-free survival (investigator-assessed)
Clinical trial · Phase 3
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
N Engl J Med · 2016
Hazard ratio 0.56 (95% CI 0.43–0.72)Progression-free survival (PFS)
Clinical trial · Phase 3
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
N Engl J Med · 2015
9.2 monthsMedian PFS — palbociclib + fulvestrant
Clinical trial · Phase 3
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
N Engl J Med · 2012
18.5 months vs 12.4 months (pertuzumab group vs control)Median progression-free survival (independent assessment)
Nothing found.